$KURA

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

Kura Oncology (KURA) will host a webcast on Oct. 13 with Caspian Therapeutics to discuss Caspian's formation and preclinical diabetes data for KO-7246, a menin inhibitor in development for metabolic applications. The webcast follows data presented at EASD.

JPMorgan initiated coverage of Kura Oncology with an overweight rating and a $30 price target, citing strong sales of its approved cancer drug Komzifti and potential of its experimental drug darlifarnib. Komzifti's revenue grew from $2.1M to $9.1M in Q2 2026, with estimated peak sales of $1.5B. Shares were up 1% on Thursday.

JPMorgan initiated Kura Oncology (KURA) with an overweight rating and $30 price target, citing strong potential in its oncology drugs. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M. Insider purchases and positive analyst revisions also supported the stock, which has gained 28% over six months.

Kura Oncology's COO, Kathleen Ford, sold 10,574 shares for $111,930, at prices between $10.50 and $10.87. The sales were to cover taxes from vesting PSUs. Kura's stock is down 2.1% weekly but up 32.9% in six months. The company's Q2 2026 earnings beat expectations, with revenue of $20.87M and adjusted loss of $0.77 per share. CEO Troy Wilson bought 100,000 shares. Analysts maintain a $24.00 price target.

Caspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.

Burrows Francis (Chief Scientific Officer) sold 20,726 shares of Kura Oncology, Inc. (KURA) at $10.83 ($0.22M total) on 2026-09-24.

Kura Oncology (KURA) contributed KO-7246 to Caspian Therapeutics, receiving equity, reimbursement, and service fees. Caspian raised $50M for diabetes and cardiometabolic programs. Kura retains partial ownership and board representation. Kura's core focus remains ziftomenib in AML, with analysts projecting $353.2M revenue and $67.2M earnings by 2029. The Caspian deal adds cardiometabolic upside without significant R&D spending for Kura.

Kura Oncology spun out Caspian, a diabetes-focused company, with $50m in funding led by BVF Partners. Kura retains 50% ownership. Caspian will develop KO-7246, a menin inhibitor for diabetes, using the funds for IND-enabling studies and a second undisclosed inhibitor. Investors include Eli Lilly and T1D Fund.

Kura Oncology's research on a leukemia drug targeting menin showed potential for treating diabetes. The company launched Caspian Therapeutics with $50M in funding to develop menin inhibitors for diabetes and other cardiometabolic diseases. Kura retains 50% ownership, and Caspian will advance its lead drug through early-phase trials.